Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) have been assigned an average rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $39.20.

Several research firms have weighed in on SYRE. Stifel Nicolaus raised their price target on Spyre Therapeutics from $36.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, March 26th. Wells Fargo & Company upgraded Spyre Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $12.00 to $35.00 in a research report on Friday, March 1st.

Spyre Therapeutics Trading Up 3.4 %

NASDAQ:SYRE opened at $33.56 on Tuesday. The firm has a 50-day simple moving average of $34.92. Spyre Therapeutics has a twelve month low of $2.66 and a twelve month high of $47.97. The stock has a market cap of $1.21 billion, a PE ratio of -0.45 and a beta of 2.88.

Spyre Therapeutics (NASDAQ:SYRE) last released its quarterly earnings results on Thursday, February 29th. The company reported ($2.28) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($1.80). As a group, equities analysts expect that Spyre Therapeutics will post -2.36 earnings per share for the current fiscal year.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).